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Rheumatic fever (RF) and rheumatic heart disease (RHD) are sequelae of group A strepto-
coccal (GAS) infection. Although an autoimmune process has long been considered to be
responsible for the initiation of RF/RHD, it is only in the last few decades that the mech-
anisms involved in the pathogenesis of the inflammatory condition have been unraveled
partly due to experimentation on animal models. RF/RHD is a uniquely human condition and
modeling this disease in animals is challenging. Antibody and T cell responses to recom-
binant GAS M protein (rM) and the subsequent interactions with cardiac tissue have been
predominantly investigated using a rat autoimmune valvulitis model. In Lewis rats immu-
nized with rM, the development of hallmark histological features akin to RF/RHD, both in
the myocardial and in valvular tissue have been reported, with the generation of heart tissue
cross-reactive antibodies and T cells. Recently, a Lewis rat model of Sydenham’s chorea
and related neuropsychiatric disorders has also been described. Rodent models are very
useful for assessing disease mechanisms due to the availability of reagents to precisely
determine sequential events following infection with GAS or post-challenge with specific
proteins and or carbohydrate preparations from GAS. However, studies of cardiac function
are more problematic in such models. In this review, a historical overview of animal models
previously used and those that are currently available will be discussed in terms of their
usefulness in modeling different aspects of the disease process. Ultimately, cardiologists,
microbiologists, immunologists, and physiologists may have to resort to diverse models to
investigate different aspects of RF/RHD.
Keywords: animal models, rheumatic fever, rheumatic heart disease, group A Streptococcus, molecular mimicry,
autoimmune responses
INTRODUCTION
Animal experimentation has been used for centuries to bet-
ter understand human physiology and pathological processes, to
improve diagnosis and to develop safe intervention, treatment, and
prevention strategies. References to animal experimentation are
found in the writings of the Greek philosopher–physician, Aris-
totle (384–322 BC) who was the first to carry out dissections.
Later, Erasistratus (304–250 BC) was probably the first to per-
form experiments on living animals. However, it was Galen (AD
130–200) who justified animal experimentation as an arduous
path to the truth, believing that assertions not based on exper-
imentation do not lead to scientific progress (1). The twelfth
century Arab physician, Ibn Zuhr (Avenzoar), introduced ani-
mal testing as an experimental technique for testing procedures
before applying them to human patients (2). A valid animal
model of a specific disease requires the process that initiates and
perpetuates the pathological mechanisms to be identical or sim-
ilar in the animal to that of the human condition that is being
modeled.
Group A streptococci that trigger rheumatic fever (RF) and
rheumatic heart disease (RHD) are uniquely human pathogens,
with no other known natural host or environmental reser-
voir. Major shortcomings associated with research into RF/RHD,
which may rely on studying human heart tissue from surgery
or autopsy tissue from patients include heterogeneity and the
ability to obtain sufficient numbers of high quality tissue spec-
imens. Therefore, the availability of an animal model in which
the pathogenic mechanisms responsible for RF/RHD could accu-
rately be reproduced is crucial for furthering our understand-
ing of the disease process, designing treatment and for testing
efficacy, and safety of vaccine candidates against group A strep-
tococci (GAS). Following the review of published literature on
animal models for RF/RHD research in the last 85 years, we out-
line briefly the models that have been used to investigate the
pathogenesis of RF/RHD. We outline the recent work on rodents
and in particular rats, that have been instrumental in modeling
some of the cardinal immunopathological features observed in
RF/RHD.
EARLY EXPERIENCE WITH ANIMAL MODELS
Developments in molecular biology, genomics, transgenic, and
cloning techniques have enabled researchers to study human
pathology in animals in greater depth. By investigating and iden-
tifying homologous genes across species, researchers can translate
experimental data from animals to humans. The overwhelming
majority of animals used in biomedical research are rodents such
as mice and rats. These are ideal animal models because they are
small, easy to handle, reproduce rapidly, have a relatively short
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Table 1 | Immunopathological changes in rodents investigated as models for rheumatic heart disease.
Antigen (route of
inoculation)
Histological changes Antibody
response
T cell response
cytokine production
Cross-reactivity References
RATS (Rattus norvegicus)
Whole GAS (FP, SC) Myocarditis, valvulitis
lymphocyte, monocyte,
MØ, giant cell, Aschoff-like
cell, fibroblast
Anti-myocardial
IgG
NA Valvular protein,
myocardial protein
Cavelti (3), Huang et al
(4), Xie et al (5)
Recombinant proteins
or peptides of GAS (SC,
IP, FP)
Myocarditis, valvulitis
T cell, MNC, neutrophil,
Anitschkow-like cell
Anti-GAS IgG CD3+, CD4+, CD8+,
CD68+, TCR-αβ+
Cardiac myosin Quinn et al (6), Lymbury
et al (7), Gorton et al (8),
Gorton et al (9), Kirvan
et al (10)
MICE (Mus musculus)
Cell wall fragments of
GAS (IP)
Myocarditis
MNC, PMNC, giant cell,
Anitschkow-like cell
Anti-GAS IgG NA NA Ohanian et al (11)
Recombinant protein of
GAS (IP)
NA Collagen IV
reactive IgG
NA Basement membrane
collagen
Dinkla et al (12)
GUINEA PIG (Cavia porcellus)
Whole GAS (IP, IV) Myocarditis, valvulitis
MNC
NA NA NA Gross et al (13)
Cell wall fragments of
GAS (FP)
NA Anti-GAS IgG NA Cardiac sarcolemmal
membrane
Yang et al (14)
NA, not assessed; IV, intra-venous; SC, sub-cutaneous; IP, intra-peritoneal; FP, foot pad; MNC, mononuclear cell; PMNC, polymorphonuclear cell; MØ, macrophage;
Ig, immunoglobulin; CD, cluster of differentiation; IFN, interferon; TCR, T cell receptor.
life span and are relatively inexpensive to maintain in a laboratory
setting. One of the major impediments in the field of RF/RHD
research has been the lack of a universally accepted animal model.
Furthermore animals are not easily infected by GAS: even when
GAS infection is initiated, it is usually not sustained for extended
periods of time.
Early experimental work to produce a suitable animal model of
RF/RHD was based on the hypotheses that RF/RHD was caused
either by persistent sub-clinical infection by GAS or by direct
injury to cardiac tissue by GAS toxins. Therefore, most studies
involved the introduction of whole bacteria or crude streptococ-
cal preparations into various animals including mice, rats, guinea
pigs (Table 1), rabbits, or non-human primates. While it was
possible to observe myocardial necrosis, myocarditis, and endo-
carditis following immunization with GAS, none of the patho-
logical lesions were considered representative of the hallmarks
of RF/RHD, the development of Aschoff nodules and valvulitis.
Animal models of RF/RHD developed prior to the 1970s paral-
leled the hypotheses for the causation of the disease process that
were dominant at the time. When it became increasingly evident
that the development of the inflammatory process observed in
RF/RHD was immune-mediated, animal models were increasingly
used to determine the role of host cross-reactive antibodies that
developed post GAS infection. Although functional studies may
be preferable in larger animals such as non-human primates, the
prohibitive costs, and paucity of specific immunological reagents
make such models less appropriate to determine the pathogenesis
of RF/RHD.
CURRENT CONCEPTS OF PATHOGENESIS OF RHEUMATIC
HEART DISEASE
The pathogenesis of RF/RHD involves three principal elements: an
infection caused by a specific strain of GAS, a susceptible host, and
an aberrant immune response against GAS antigens that cross-
react with host tissue (15, 16). The manifestations of RF/RHD
are due to inflammatory changes that occur in cardiac tissue,
joints, brain, blood vessels, and skin. Rheumatic carditis is the
most serious consequence of the disease process while migratory
polyarthritis and the neurologic manifestation Sydenham chorea
(SC) may present in conjunction with carditis. Other clinical signs
include the development of erythema marginatum and subcuta-
neous nodules (16). Host–GAS interactions initiating the immune
responses cause carditis with subsequent GAS infections potenti-
ating the disease process resulting in a cascade of events that cause
hemodynamic changes culminating in irreversible cardiac damage
and decompensatory cardiac failure.
Monoclonal antibodies derived from RF/RHD patients have
provided evidence for cross-reactive autoantibodies that target
GAS epitopes such as group A carbohydrate, N -acetyl-beta-d-
glucosamine (GlcNAc), and M protein with host proteins includ-
ing heart valve endothelium, laminin, and laminar basement
membrane and cardiac myosin [Reviewed in Ref. (17, 18)]. GAS M
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proteins have been studies extensively and it is one of the important
GAS proteins involved in inducing the autoimmune process. Over
220 different variants of the M protein have been described (19).
While identification of M proteins is useful for epidemiological
and vaccine studies not all GAS M types are implicated in the devel-
opment of RF/RHD. Peripheral blood and heart-infiltrating T cells
from patients with RF/RHD have revealed cross-reactivity of GAS
M protein specific T cells with cardiac myosin. Experimental and
clinical evidence suggests that antibodies interact with valvular
endothelium and activate adhesion molecules with subsequent
extravasation of T cells through the activated endothelium into
the valve leading to the formation of granulomatous lesions. The
inflammatory process that is thus triggered by antibodies to GAS
infection activates adhesion molecules such as VCAM and ICAM,
which play a role in the migration of leukocytes into the valvular
tissue (17, 18). It has been demonstrated in patients with RF/RHD
that specific chemokine genes, such as CXCL3 in the myocardium
and CCL1 and CXCL9 in valvular tissue are upregulated (20).
These chemokines could potentially mediate T cell recruitment to
areas of inflammation. The specific cytokines produced by periph-
eral and heart-infiltrating T cells in patients have been identified
(21) suggesting that Th1 and Th17 cells are involved in the devel-
opment of carditis. Such cytokine profiles have also been observed
in other autoimmune inflammatory conditions (22). Additionally
the low levels of IL-4 produced by T cells infiltrating the valvular
tissue may potentially contribute to the progression of valvular
pathology (21).
Repeated GAS infection also leads to neovascularization within
heart valves resulting in increased mononuclear cell infiltra-
tion resulting in cardiac and valvular damage. This process may
also involve autoantibodies generated via epitope spreading fol-
lowing immune recognition of other components of the car-
diac tissue such as vimentin and collagen released during tissue
destruction (17).
One of the major manifestations associated with RF/RHD is
SC. It has been found that antibodies from SC patients target the
GAS carbohydrate epitope GlcNAc and react with gangliosides
and dopamine receptors found on the surface of neuronal cells
in the brain. These antibodies have been found to activate cal-
cium calmodulin-dependent protein kinase II in neuronal cells
and recognize the intracellular tubulin (23).
Molecular mimicry between GAS antigens and host antigens
has been shown to initiate and potentiates the development of the
clinical manifestations observed in RF/RHD. GAS have a variety
of antigens and superantigens that are able to stimulate robust
B and T cell responses to autoantigens (17, 18). Both human
and animal studies have provided evidence that have been useful
in formulating the potential mechanisms that lead to the post-
infectious autoimmune sequelae. Animal models of RF/RHD and
SC have been important in characterizing mimicry in carditis and
SC as well as attempting to identify the pathogenic epitopes of the
autoantigens and GAS antigens involved in the pathogenesis of
RF/RHD. However, several facets of the pathological process at a
cellular and molecular level that initiate inflammatory changes in
the different organs and tissue in RF/RHD remain undefined. Fun-
damental concepts including which GAS strains and what combi-
nation of GAS antigens are involved in the breakdown of tolerance
during the disease process are unclear. Studies to address some
of these fundamental issues require the use of well characterized
animal models that encompass the features observed in RF/RHD.
USE OF RODENT MODELS TO DETERMINE THE
AUTOIMMUNE PROCESS
To further investigate the pathogenesis of RF/RHD and in par-
ticular to determine the contribution of autoreactive B and T
cells in the RF/RHD pathogenesis, suitable animal models were
investigated. Huber and Cunningham (24) produced myocarditis
in MRL+/+ mice immunized with specific N-terminal peptides
of GAS M5. These studies were one of the first to demonstrate
that mimicry between a pathogen derived epitope and a host pro-
tein could break tolerance and trigger an autoimmune process in
a susceptible host. The same group at the Oklahoma University
Health Sciences Center subsequently developed a more robust
animal model for RF/RHD (6, 25). Female Lewis rats immu-
nized with GAS M protein (Figure 1A) exhibit myocardial lesions
similar to those observed in patients with RF/RHD. More impor-
tantly, valvular pathology was observed for the first time using
this model (5–8, 10, 25). This model is discussed in more detail
below.
In recent years extensive work on murine models have been
conducted to determine the efficacy of anti-GAS vaccine candi-
dates in terms of their ability to protect against GAS infections
(18, 26, 27). These murine models have been used mostly if not
exclusively to determine vaccine efficacy. Although an HLA class
II transgenic mouse model has been used to investigate both the
protective immune responses induced by a vaccine candidate and
determine whether it induces histological changes in host tissue
(26), this model may not be very appropriate for the purpose
of determining cross-reactivity in host tissue. A year following
immunization with the candidate vaccine preparation the investi-
gators did not observe any histological changes in various organs
in the immunized mice. Although the vaccine preparation was
considered to be safe, control transgenic mice developed addi-
tional complications. These complications may deter researchers
from using such a model to investigate tissue cross-reactivity and
vaccine safety.
RAT AUTOIMMUNE VALVULITIS MODEL OF RHEUMATIC
HEART DISEASE
The Lewis rat model of RF/RHD developed in the late 90s (6),
exhibited myocardial lesions similar to those observed in RF/RHD
following immunization with GAS M6 protein (Figure 1). More
importantly, this Lewis rat model is the first in which valvu-
lar changes akin to human pathology has been demonstrated.
Valvular lesions observed at the valve surface endothelium spread
into the valve. Anitschkow cells and verruca-like lesions have
also been observed. Due to the valvular involvement observed
in immunized animals, this model has been referred to as the rat
autoimmune valvulitis (RAV) model (8). T cells from recombinant
M6-immunized (rM6) rats proliferated in vitro in the presence of
cardiac myosin. In addition a T cell line produced from GAS rM6-
immunized rats proliferated in the presence of cardiac myosin and
GAS rM6 protein. When Galvin and colleagues (25) co-cultures
myosin-sensitized lymphocytes isolated from the hearts of Lewis
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FIGURE 1 | Immunization protocol for the induction of autoimmune
valvulitis in Lewis rats and the immunological, histological, and
functional changes following immunization with recombinant
streptococcal M protein. (A)The induction of valvulitis in the rat
autoimmune valvulitis (RAV) model of RF/RHD involves a primary
immunization of female Lewis rats (under isoflurane anesthesia) with
500µg GAS rM5 protein (or PBS as a negative control) in complete Freund’s
adjuvant (CFA) administered subcutaneously (s.c.) in the hock on day 0. On
days 1 and 3, rats are injected intraperitoneally (i.p.) with an additional
adjuvant being either 0.3µg commercially purchased pertussis toxin [PTx;
(7)] or 1010 CFU formalin-killed Bordetella pertussis (6, 8, 9) each in 200µl
PBS. On day 7, rats receive a booster immunization with 500µg GAS rM5
protein (or PBS as a negative control) in incomplete Freund’s adjuvant (IFA)
administered s.c. in the flank under anesthesia. On day 21, the rats are
euthansed by CO2 asphyxiation to harvest blood and organs for histological
examination of heart tissue and determination of GAS rM5-specific antibody
levels and assessment of T cell function. (B) GAS rM5-specific IgG
antibodies in rat (n= 5) serum were detected by ELISA. The highest serum
dilution that was positive for GAS rM5-specific IgG antibodies (cut-off value
3 SD higher than the mean for the known negative control serum) was
recorded as the serum titer. Serum from rats immunized with GAS rM5
contained significantly higher GAS rM5-specific antibodies compared to
control (P =0.007). (C) Proliferative response of GAS rM5-specific T cells
from spleens of rats (n=5) was determined by 3H-thymidine incorporation
assay and found to be significantly higher than in controls immunized with
PBS (P =0.009). Bars depict the mean±SEM. **P ≤0.01.
Immunohistological changes (D,E) in representative valvular tissue and
myocardium (inset) from (D) controls and (E) rM5-immunized animals.
Immunohistochemical staining of infiltrating mononuclear cells
demonstrates the presence of CD4+T cells in rM5-immunized animals
compared to controls. Scale bar indicates 50µM (DAB staining). (F) ECG
complexes from a control and a rM5-immunized rat demonstrate
significantly longer P-R interval in the rM5-immunized rats (Images courtesy
of Dr Lisa Chilton, James Cook University). (G) Echocardiographs from
control and an rM5-immunized rat demonstrate reduction in fractional
shortening due to reduced LV contractility. Bars represent the width of the
left ventricle (LV) chamber during contraction (*Images courtesy of Drs Lisa
Chilton and Jane Day, James Cook University).
rats with peptides of GAS M5 protein, heart-infiltrating lym-
phocytes proliferated in response to peptides within the B-repeat
region of the GAS M protein. Their work provided evidence that
an immune response against cardiac myosin could potentially lead
to valvular heart disease and the infiltration of the heart by GAS
M protein-reactive T cells.
Using the same protocol to initiate valvulitis, Lymbury et al. (7)
demonstrated that 80% of Lewis rats immunized with a pool of
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15, 20-mer overlapping peptides spanning the conserved C-repeat
region of the GAS M5 developed inflammatory lesions in both the
myocardium and valvular tissue. These studies highlighted the role
for GAS M protein-specific autoreactive T cells in the development
of cardiac lesions. T cells from rats immunized with the conserved
region peptides proliferated in response to the immunogen and
to cardiac myosin. Further proof of the role of both humoral and
cellular responses (Figures 1B–E) in the pathogenesis of RF/RHD
was demonstrated by Gorton et al (8). It was found that GAS
rM5 protein elicited opsonic antibodies in Lewis rats, which rec-
ognized epitopes within the B- and C-repeat regions of M5. A
single peptide from the GAS M5 B-repeat region induced lympho-
cytes that responded to both recombinant M5 and cardiac myosin.
Additionally, it was found that rats immunized with GAS rM5
protein developed valvular lesions (Figures 1D,E), distinguished
by infiltration of CD3+, CD4+, and CD68+ cells into valve tis-
sue, consistent with human studies. This suggests that RF/RHD is
mediated by inflammatory responses involving both CD4+T cells
and macrophages. Recent proof of concept work undertaken by
this group on the RAV model has also demonstrated that repetitive
immunization with GAS rM5 increases both B and T cell sensitiza-
tion leading to increased inflammatory cell infiltration that could
potentially lead to severe cardiac damage. This observation fur-
ther demonstrates that the immunopathology in the RAV model
reflects the human condition, where repetitive GAS infections lead
to exacerbation of RF/RHD, which culminates in cardiac failure.
The Lewis rat model has also been used to immunize with
formalin-killed and sonicated GAS (5). The investigators were
able to demonstrate in rats killed 12 weeks following immuniza-
tion only 50% (4/8) developed myocarditis and valvulitis. In
contrast, animals sacrificed 24 weeks following GAS immuniza-
tion demonstrated myocardial and valvular damage and devel-
oped rheumatic-like myocarditis with 62.5% (5/8) developing
chronic valvulitis. Histological manifestations of the hearts in
this group demonstrated “Aschoff-like” cells, verrucous vegeta-
tion,and chronic lesions including fibrosis and neovascularization,
hallmark of chronic rheumatic valvulitis.
To identify the epitopes of M5 protein that produce valvulitis,
and to prove that M protein-specific T cells may be important
mediators of valvulitis, Kirvan and colleagues (10) used synthetic
peptides spanning all three repeat regions of GAS M5 (A, B, and
C-repeat regions) contained within the extracellular domain of
the streptococcal M5 protein to immunize Lewis rats. Peptides
NT4, NT5/6, and NT7 from the A repeat region induced valvulitis
similar to the pepsin fragment of M5 protein. T cell lines from
rats with valvulitis also recognized peptides NT5/6 and NT6. They
also conducted passive transfer of a NT5/6-specific T cell line into
naïve rats, which produced valvulitis with characteristic CD4+ T
cell infiltration and upregulation of VCAM demonstrating exper-
imentally that M protein-specific T cells are important mediators
of valvulitis.
To our knowledge the RAV model has not been widely used
to investigate the safety of anti-GAS vaccine candidates by assess-
ing their potential to initiate autoimmune pathology. However,
prior to a recent human Phase 1 clinical trial for a GAS vaccine
based on the J8 construct, the RAV model was used to test for
safety of the vaccine preparation. None of the animals immunized
with the vaccine preparation in the authors’ laboratory developed
either carditis or valulitis. While the RAV model has been useful in
characterizing key aspects involved in the autoimmune process in
RF/RHD pathogenesis, its potential has not yet been fully realized.
Extensive characterization of cardiac function in the RAV model
(Figures 1F,G) may lead to greater acceptance of the RAV model
among researchers working on different aspects of RF/RHD.
RAT MODEL FOR SYDENHAM’S CHOREA
One of the manifestations of RF/RHD is the development of the
SC, which is a neurological disorder characterized by rapid, unco-
ordinated jerking movements affecting the face, hands, and feet.
Although it is reported to occur in a quarter of patients with
RF/RHD in some regions, it may also be the presenting symptom
of RF/RHD (16). A team of researchers from Tel Aviv University
and the Oklahoma University Health Sciences Center developed
a model for SC using male Lewis rats, which were exposed to
GAS antigen (28, 29). Following immunization with GAS, the rats
exhibited neurological motor symptoms and compulsive behav-
ior. These symptoms were alleviated by the D2 blocker haloperidol
and the selective serotonin reuptake inhibitor paroxetine, medica-
tions that are used to treat motor symptoms and compulsions in
GAS-related neuropsychiatric disorders. Recent studies published
by these investigators revealed that antibodies purified from the
sera of GAS-exposed rats and infused into the striatum of naïve
rats led to behavioral and motor alterations mimicking those seen
in GAS-exposed rats (29). IgG from GAS-exposed rats reacted
with dopamine and serotonin receptors in vitro, demonstrating the
potential pathogenic role of autoantibodies produced following
exposure to GAS.
SUMMARY
There are many fundamental immunological questions that need
to be answered if effective RF/RHD control strategies are to be
implemented worldwide. These questions include: (1) the iden-
tity and dominant hierarchy of streptococcal antigens in dri-
ving immune-mediated cardiac pathology; (2) the precise cell-
mediated and antibody mechanisms involved in disease initiation
and progression; and (3) whether disease can be prevented by
regulating or switching off pathogenic immune responses. Target-
ing key processes involved in disease mechanisms, i.e., regulation
of destructive immune responses directed against the host, may
provide adjunct management strategies for RF/RHD. The RAV
model is currently the only model available that is suitable for
such investigations.
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